September 14, 2016
Tizona Therapeutics, Inc. Appoints George Golumbeski, Ph.D., to its Board of Directors
SOUTH SAN FRANCISCO, Calif., August 30, 2016 – Tizona Therapeutics, Inc., a privately held immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases, today announced that George Golumbeski, Ph.D., has joined the company’s board of directors. Dr. Golumbeski brings more than 25 years of executive leadership experience in R&D and business development in the biotechnology and pharmaceutical industry to Tizona. “George’s extensive experience in bringing numerous medicines to patients and in forging creative and effective collaborations within the biotech and pharmaceutical industry makes him an ideal addition to the Tizona board of directors,” said Pablo J. Cagnoni, President and Chief Executive Officer of Tizona. “George’s addition to our board provides us with a critical strategic perspective as we continue to build Tizona.” “Tizona is taking multiple approaches to target the mechanisms responsible for immune suppression in the tumor microenvironment,” said Dr. Golumbeski. “I am pleased to join the board of directors to work alongside Tizona’s strong team of scientific founders and advisory board members to realize the company’s goal of bringing next generation immuno-therapies to patients.” Dr. Golumbeski currently serves as Executive Vice President of Business Development for Celgene Corporation, where he is responsible for worldwide business development activities, including evaluation of opportunities, structuring and negotiating collaborations, mergers and acquisitions, and alliance management. Prior to Celgene, he was Chief Executive Officer at Nabriva Therapeutics AG, where from 2008-2009, he led the company’s transition toward a development company. From 2002 to 2008, Dr. Golumbeski was Vice President, Business Development, Licensing and Strategy at Novartis-Oncology, a business unit within Novartis, where he was a member of the Executive Committee, which was responsible for the overall results of the business unit franchise. Dr. Golumbeski has also held several business and corporate development positions of increasing responsibility at Elan Pharmaceuticals, EMD Pharmaceuticals and Schwarz Pharma. Dr. Golumbeski earned a Bachelor of Arts in Biology from the University of Virginia and a Ph.D. in Genetics from the University of Wisconsin-Madison. He currently serves on the Board of Directors of Enanta Pharmaceuticals, Acceleron Pharma and of the National Audubon Society.
About Tizona Therapeutics, Inc. Tizona Therapeutics, Inc. Tizona Therapeutics, Inc., is a privately held immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune disorders. A healthy immune system integrates information from pro-inflammatory and anti-inflammatory cells that regulate the immune system’s function. In cancer, tumor cells evade recognition by controlling cells that suppress the proper function of the immune system. In autoimmune disease, the immune system attacks “self” tissues in the body due to insufficient regulation. Tizona’s therapies are designed to regulate these suppressive cells, thereby either activating the body’s ability to fight cancer or preventing the immune system from attacking healthy tissues in autoimmune diseases. For more information, visit www.tizonatx.com.
Media Contact: Lori Melançon, Communications Consultant, Tizona Therapeutics, Inc., 1-650-684-7141.